Mounjaro (tirzepatide) can be an effective weight-loss medicine, but it is not suitable for everyone. This guide explains who should not use Mounjaro, who needs extra clinical review before starting, and which red-flag symptoms mean you should stop and get urgent medical help.

If you’re still learning the basics first, read Mounjaro – Weight Loss Benefits & UK NHS Guidance and Mounjaro Eligibility (NHS vs Private Criteria) before booking a consultation.

Safety note: This is educational information, not a diagnosis. Your prescriber must confirm suitability.

Table of Contents

Quick safety decision table (most useful for patients)

Situation	What it means for Mounjaro
Allergy to tirzepatide or ingredients	Do not use (contraindicated).
Pregnant / trying / not using contraception	Should not be used; stop if pregnancy occurs.
Breastfeeding	Risk to infant can’t be ruled out; decide with clinician (often avoid/delay).
Severe digestion problems (incl. severe gastroparesis)	Needs clinician review; may be unsuitable.
Severe abdominal pain (esp. with/without vomiting)	Stop + urgent help (possible pancreatitis).
Breathing trouble / swelling lips/tongue/throat	Emergency help (possible anaphylaxis/angioedema).
Using insulin or sulfonylurea	Higher hypo risk; dosing plan + monitoring needed.
Repeated vomiting/diarrhoea, dehydration	Kidney function can worsen; contact clinician early.

1) Absolute contraindication: who must NOT use Mounjaro

You must not use Mounjaro if you are allergic to it

Mounjaro is contraindicated if you have hypersensitivity to tirzepatide or any of the product ingredients.

What to do: If you’ve ever had a serious reaction to injectable medicines, tell your prescriber during the Online Weight Loss Consultation: What MedCare Asks & Why so they can assess risk properly.

2) Pregnancy + contraception: who should not start (or must stop)

Pregnancy

The patient leaflet states Mounjaro should not be used during pregnancy because effects on the unborn child are not known.
NICE prescribing resources also emphasise it’s not recommended in pregnancy and should be stopped if pregnancy occurs.

Contraception (important detail many people miss)

The leaflet recommends using contraception while using Mounjaro, and adds a practical rule: if you have obesity/overweight and use oral contraceptives, consider a barrier method or switching to a non-oral contraceptive for 4 weeks after starting and 4 weeks after each dose increase.

Bottom line: If pregnancy is possible and contraception isn’t reliable, Mounjaro usually isn’t appropriate until this is clinically managed.

3) Breastfeeding: usually avoid unless clinician decides otherwise

It’s unknown whether tirzepatide passes into breast milk; a risk to infants cannot be ruled out. The leaflet advises discussing with your clinician and deciding whether to stop breastfeeding or delay treatment.

4) Under 18: not for children or adolescents

Mounjaro should not be given to people under 18 because it hasn’t been studied in that age group.

5) Severe stomach / digestion problems: caution category

If you have severe problems with food digestion or food staying in the stomach longer than normal (including severe gastroparesis), the leaflet says to speak to your clinician before using Mounjaro.

Why it matters: delayed gastric emptying is part of how the medication works, so severe baseline digestive motility problems can become harder to manage.

6) Pancreatitis: history + urgent symptoms you must act on

If you’ve ever had pancreatitis

The patient leaflet flags prior pancreatitis as something your clinician must know before starting.
The UK SmPC also notes tirzepatide hasn’t been studied in people with a history of pancreatitis and should be used with caution.

Red flags: stop and get urgent help

The leaflet is very direct: acute pancreatitis can happen (uncommon), and you should seek urgent care if you get:

Severe, persistent abdominal pain (with or without nausea/vomiting), sometimes radiating to the back.

The SmPC also instructs that people should be informed about symptoms and seek immediate medical attention; if pancreatitis is suspected, tirzepatide should be discontinued.

7) Severe allergic reaction (anaphylaxis/angioedema): emergency rule

Rarely, severe allergic reactions can occur. The leaflet lists emergency symptoms such as:

breathing problems
rapid swelling of lips, tongue and/or throat with difficulty swallowing
fast heartbeat
and says to get immediate medical help.

8) Higher hypoglycaemia risk: insulin and sulfonylureas

If Mounjaro is used with insulin or a sulfonylurea, low blood sugar can occur and your clinician may need to adjust doses.
The leaflet also lists typical hypo symptoms (e.g., dizziness, hunger, confusion, sweating, fast heartbeat).

Practical meaning: this isn’t always a “do not use,” but it is a do not self-start situation-your dosing and monitoring plan matters.

9) Vomiting/diarrhoea → dehydration → kidney function risk

When starting treatment, some people experience fluid loss/dehydration from nausea, vomiting, or diarrhoea, which may reduce kidney function. The leaflet advises avoiding dehydration and contacting a clinician if concerned.

10) Gallstones and gallbladder inflammation: know the signs

In the leaflet’s side effects list, gallstones are noted (with different frequencies depending on weight management vs diabetes use), and cholecystitis (gallbladder infection/inflammation) is also listed.

What this means for “who should not”:

If you have a history of gallbladder disease, tell your prescriber early during your Online Weight Loss Consultation so they can weigh risks and monitoring.

11) Surgery / anaesthesia: you must disclose

If you are due to have surgery under anaesthesia, the leaflet says you should tell your doctor that you are taking Mounjaro.

12) “Not right for you” can also mean “not benefiting enough”

For weight management, the UK SmPC includes a review rule: if a patient hasn’t lost at least 5% of initial body weight 6 months after titrating to the highest tolerated dose, a decision is needed on whether to continue, based on benefit/risk.

This is part of responsible prescribing and ties into the NHS concept of ongoing clinical oversight.

13) Why MedCare (and the NHS) emphasise wraparound care

NHS England’s January 5, 2026 publication explains that when tirzepatide is prescribed for weight management, structured wraparound care is a required treatment component, combining:

clinical support (eligibility assessment, safe prescribing, regular reviews, side effects, interactions, non-responder identification)
behavioural support (structured diet/activity habit support designed for patients on the medicine)

This is the safety backbone behind your consultation and follow-ups.

Quick “tell your prescriber” checklist (copy/paste friendly)

Tell your clinician before starting if any apply:

past allergy to tirzepatide or severe allergic reactions to injectables
pregnant, planning pregnancy, or contraception uncertainty
breastfeeding or planning to breastfeed
severe gastroparesis or major ongoing digestive disease
history of pancreatitis
using insulin or a sulfonylurea
frequent vomiting/diarrhoea, dehydration risk, or kidney issues
gallbladder disease history (gallstones/cholecystitis risk awareness)
upcoming surgery/anaesthesia